

## DAFTAR PUSTAKA

- Aarnink, E., Zabern, M., Boersma, L., dan Glikson, M., 2023. Mechanisms and Prediction of Ischemic Stroke in Atrial Fibrillation Patients. *Journal of Clinical Medicine*, **12**: 6491.
- Adeyana, S., Haryadi, H., dan Wijaya, C., 2018. Hubungan Kejadian Fibrilasi Atrium dengan Diameter Atrium Kiri pada Fibrilasi Atrium Valvular dan Fibrilasi Atrium Non-Valvular Di RSUD Arifin Achmad. *Jurnal Ilmu Kedokteran*, **11**: 31.
- Ahadiyah, I., Ardianto, P., Wahyudi, F., dan Sobirin, M.A., 2023. Bioscientia Medicina: Journal of Biomedicine & Translational Research.
- Al-Amer, O.M., 2022. The role of thrombin in haemostasis. *Blood Coagulation & Fibrinolysis*, **33**: 145–148.
- Alshehri, A., 2019. Stroke in atrial fibrillation: Review of risk stratification and preventive therapy. *Journal of Family and Community Medicine*, **26**: 92.
- Anand, A., Kumar, R., Gupta, A., Vijayvergiya, R., Mehrotra, S., Lad, D., dkk., 2022. Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting. *Indian Heart Journal*, **74**: 245–248.
- Apostolakis, S., Sullivan, R.M., Olshansky, B., dan Lip, G.Y.H., 2013. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin. *Chest*, **144**: 1555–1563.
- Bhattacharyya, A., Bhavnani, M., dan Tymms, D.J., n.d. Serious interaction between digoxin and warfarin.
- Bloukh, D., Hijazeen, S., dan Al-Noimi, F., 2018. Effect of Diuretics on the Pharmacologic Action of Warfarin.
- Celik, A., Izci, S., Kobat, M.A., Ates, A.H., Cakmak, A., Cakilli, Y., dkk., 2015. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: warfarin -tr. *The Anatolian Journal of Cardiology*, .
- Chan, N., Orchard, J., Agbayani, M., Boddington, D., Chao, T., Johar, S., dkk., 2022. 2021 Asia Pacific Heart Rhythm Society (APHRS) practice guidance on atrial fibrillation screening. *Journal of Arrhythmia*, **38**: 31–49.
- Choi, S.E., Sagris, D., Hill, A., Lip, G.Y.H., dan Abdul-Rahim, A.H., 2023. Atrial fibrillation and stroke. *Expert Review of Cardiovascular Therapy*, **21**: 35–56.

- Costa Viana, C., Da Silva Praxedes, M.F., Freitas Nunes De Sousa, W.J., Bartolazzi, F., Sousa Vianna, M., Padilha Da Silva, J.L., dkk., 2021. Sex-influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: Systematic review and meta-analysis. *British Journal of Clinical Pharmacology*, **87**: 4488–4503.
- Cuculich, P.S. dan Kates, A.M., 2014. *The Washington Manual of Cardiology Subspecialty Consult*, The Washington Manual® Subspecialty Consult Series. Wolters Kluwer Health.
- Dai, H., Zhang, Q., Much, A.A., Maor, E., Segev, A., Beinart, R., dkk., 2021. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. *European Heart Journal - Quality of Care and Clinical Outcomes*, **7**: 574–582.
- Davis, R.C., Hobbs, F.D.R., Kenkre, J.E., Roalfe, A.K., Iles, R., Lip, G.Y.H., dkk., 2012. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. *Europace*, **14**: 1553–1559.
- De Vries, J.X., Raedsch, R., Völker, U., Walter-Sack, I., dan Weber, E., 1988. Biliary excretion of phenprocoumon and metabolites. *European Journal of Clinical Pharmacology*, **35**: 433–436.
- Dhungana, S.P. dan Ghimire, R., 2020. Prevalence of Valvular and Non-valvular Atrial Fibrillation and the Application of Antithrombotic Treatment in a Tertiary Care Hospital. *Journal of Nepal Medical Association*, **58**: .
- Dinc Asarcikli, L., Kafes, H., Department of Cardiology, Health Sciences University Ankara City Hospital, Ankara, Turkey, Sen, T., Department of Cardiology, Dumlupinar University School of Medicine, University Hospital, Kutahya, Turkey, Gucuk Ipek, E., dkk., 2021. Time in therapeutic range values of patients using warfarin and factors that influence time in therapeutic range. *Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology*, **49**: 463–473.
- Freedman, B., Potpara, T.S., dan Lip, G.Y.H., 2016. Stroke prevention in atrial fibrillation. *The Lancet*, **388**: 806–817.
- Gažová, A., Leddy, J.J., Rexová, M., Hlivák, P., Hatala, R., dan Kyselovič, J., 2019. Predictive value of CHA<sub>2</sub>DS<sub>2</sub>-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). *Medicine*, **98**: e16560.
- Grandi, E. dan Ripplinger, C.M., 2019. Antiarrhythmic mechanisms of beta blocker therapy. *Pharmacological Research*, **146**: 104274.

- Heimark, L.D., Wienkers, L., Kunze, K., Gibaldi, M., Eddy, A.C., Trager, W.F., dkk., 1992. The mechanism of the interaction between amiodarone and warfarin in humans. *Clinical Pharmacology and Therapeutics*, **51**: 398–407.
- Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist, C., dkk., 2021. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). *European Heart Journal*, **42**: 373–498.
- Hirsh, J., Fuster, V., Ansell, J., dan Halperin, J.L., 2003. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. *Circulation*, **107**: 1692–1711.
- Ho, L.L. dan Brighton, T., 2002. Warfarin, antiplatelet drugs and their interactions. *Australian Prescriber*, **25**: 81–85.
- Howard-Thompson, A., Luckey, A., George, C., Choby, B.A., dan Self, T.H., 2014. Graves' Disease and Treatment Effects on Warfarin Anticoagulation. *Case Reports in Medicine*, **2014**: 1–6.
- Huang, Y.-Q., Gou, R., Diao, Y.-S., Yin, Q.-H., Fan, W.-X., Liang, Y.-P., dkk., 2014. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. *Journal of Zhejiang University SCIENCE B*, **15**: 58–66.
- Iacobellis, G., Ribaldo, M.C., Leto, G., Zappaterreno, A., Vecci, E., Di Mario, U., dkk., 2002. Influence of Excess Fat on Cardiac Morphology and Function: Study in Uncomplicated Obesity. *Obesity Research*, **10**: 767–773.
- Inoue, H., Kodani, E., Atarashi, H., Okumura, K., Yamashita, T., Okuyama, Y., dkk., 2018. Time in Therapeutic Range and Disease Outcomes in Elderly Japanese Patients With Nonvalvular Atrial Fibrillation. *Circulation Journal*, **82**: 2510–2517.
- Irmansyah, Y.A. dan Pintaningrum, Y., 2020. Karakteristik Pasien Atrial Fibrilasi Pada Pasien Rawat Jalan Rumah Sakit Umum Daerah Provinsi Nusa Tenggara Barat Periode Januari 2015 Hingga Januari 2016.
- Jacobs, L.G., 2008. Warfarin Pharmacology, Clinical Management, and Evaluation of Hemorrhagic Risk for the Elderly. *Cardiology Clinics*, **26**: 157–167.
- Jame, S. dan Barnes, G., 2020. Stroke and thromboembolism prevention in atrial fibrillation. *Heart*, **106**: 10–17.
- JCS Joint Working Group, 2014. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013): – Digest Version –. *Circulation Journal*, **78**: 1997–2021.

- Jones, C., Pollit, V., Fitzmaurice, D., Cowan, C., dan On behalf of the Guideline Development Group, 2014. The management of atrial fibrillation: summary of updated NICE guidance. *BMJ*, **348**: g3655–g3655.
- Kaatz, S., 2008. Determinants and measures of quality in oral anticoagulation therapy. *Journal of Thrombosis and Thrombolysis*, **25**: 61–66.
- Kaminsky, L.S. dan Zhang, Z.-Y., 1997. Human P450 metabolism of warfarin. *Pharmacology & Therapeutics*, **73**: 67–74.
- Kang, S.-H., Choi, E.-K., Han, K.-D., Lee, S.-R., Lim, W.-H., Cha, M.-J., dkk., 2016. Underweight is a risk factor for atrial fibrillation: A nationwide population-based study. *International Journal of Cardiology*, **215**: 449–456.
- Kementerian Kesehatan, 2014. Peraturan Menteri Kesehatan Nomor 41 Tahun 2014 tentang Pedoman Gizi Seimbang.
- Khan, A.A. dan Lip, G.Y.H., 2019. The prothrombotic state in atrial fibrillation: pathophysiological and management implications. *Cardiovascular Research*, **115**: 31–45.
- Kirchhof, P., Camm, A.J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., dkk., 2020. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *New England Journal of Medicine*, **383**: 1305–1316.
- Ko, D., Rahman, F., Martins, M.A.P., Hylek, E.M., Ellinor, P.T., Schnabel, R.B., dkk., 2017. Atrial fibrillation in women: treatment. *Nature Reviews Cardiology*, **14**: 113–124.
- Kodani, E., Atarashi, H., Inoue, H., Okumura, K., Yamashita, T., dan on behalf of the J-RHYTHM Registry Investigators, 2015. Target Intensity of Anticoagulation With Warfarin in Japanese Patients With Valvular Atrial Fibrillation: – Subanalysis of the J-RHYTHM Registry –. *Circulation Journal*, **79**: 325–330.
- Kornej, J., Börschel, C.S., Benjamin, E.J., dan Schnabel, R.B., 2020. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. *Circulation Research*, **127**: 4–20.
- Kose, E., Arai, S., An, T., Kikkawa, A., Aoyama, T., Matsumoto, Y., dkk., 2015. Analysis of factors affecting time in therapeutic range control after warfarin administration 494–498.
- Kupczyńska, K., D. Kasprzak, J., Michalski, B., dan Lipiec, P., 2013. Prognostic significance of spontaneous echocardiographic contrast detected by transthoracic and transesophageal echocardiography in the era of harmonic imaging. *Archives of Medical Science*, **5**: 808–814.

- Laizure, S.C., Madlock, L.E., Cyr, M., dan Self, T.H., 1997. Decreased hypoprothrombinemic effect of warfarin associated with furosemide. *Therapeutic drug monitoring*, **19** 3: 361–3.
- LaMori, J.C., Mody, S.H., Gross, H.J., daCosta DiBonaventura, M., Patel, A.A., Schein, J.R., dkk., 2013. Burden of comorbidities among patients with atrial fibrillation. *Therapeutic Advances in Cardiovascular Disease*, **7**: 53–62.
- Lane, S., Al-Zubiedi, S., Hatch, E., Matthews, I., Jorgensen, A., Daly, A., dkk., 2011. The population pharmacokinetics of R- and S-warfarin: Effect of genetic and clinical factors. *British journal of clinical pharmacology*, **73**: 66–76.
- Lavie, C.J., Pandey, A., Lau, D.H., Alpert, M.A., dan Sanders, P., 2017. Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis. *Journal of the American College of Cardiology*, **70**: 2022–2035.
- Lee, K.-H., Hung, W.-T., Huang, W.-Y., Ovbiagele, B., dan Lee, M., 2024. Direct oral anticoagulants compared with other strategies in patients with atrial fibrillation and stroke or transient ischemic attack: Systematic review. *Journal of the Formosan Medical Association*, **123**: 551–560.
- Lee, S.L., Ong, T.J., Mazlan-Kepli, W., Mageswaran, A., Tan, K.H., Abd-Malek, A.-M., dkk., 2021. Patients' time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. *World Journal of Cardiology*, **13**: 483–492.
- Lemeshow, S. (Editor), 1993. *Adequacy of Sample Size in Health Studies*, Repr. ed. Wiley, Chichester.
- Libby, P., Bonow, R.O., Mann, D.L., Tomaselli, G.F., Bhatt, D.L., Solomon, S.D., dkk., 2021. *Braunwald's Heart Disease - E-Book: A Textbook of Cardiovascular Medicine*. Elsevier Health Sciences.
- Liyew, Z., Tadesse, A., Bekele, N., dan Tsegaye, T., 2021. Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia. *Advances in Hematology*, **2021**: 1–8.
- Lynch, T. dan Price, A., 2007. The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects. *Cytochrome P*, **76**: .
- Mar, P.L., Gopinathannair, R., Gengler, B.E., Chung, M.K., Perez, A., Dukes, J., dkk., 2022. Drug Interactions Affecting Oral Anticoagulant Use. *Circulation: Arrhythmia and Electrophysiology*, **15**: .
- Martin, P.D., Warwick, M.J., Dane, A.L., Hill, S.J., Giles, P.B., Phillips, P.J., dkk., 2003. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. *Clinical Therapeutics*, **25**: 2822–2835.

- Masawa, N., Yoshida, Y., Yamada, T., Joshita, T., dan Ooneda, G., 1993. Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi. *Virchows Archiv A Pathological Anatomy and Histopathology*, **422**: 67–71.
- Morgan, C.Ll., McEwan, P., Tukiendorf, A., Robinson, P.A., Clemens, A., dan Plumb, J.M., 2009. Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control. *Thrombosis Research*, **124**: 37–41.
- Morseth, B., Geelhoed, B., Linneberg, A., Johansson, L., Kuulasmaa, K., Salomaa, V., dkk., 2021. Age-specific atrial fibrillation incidence, attributable risk factors and risk of stroke and mortality: results from the MORGAM Consortium. *Open Heart*, **8**: e001624.
- Mukker, J.K., Singh, R.S.P., dan Derendorf, H., 2016. Pharmacokinetic and Pharmacodynamic Considerations in Elderly Population, dalam: Stegemann, S. (Editor), *Developing Drug Products in an Aging Society, AAPS Advances in the Pharmaceutical Sciences Series*. Springer International Publishing, Cham, hal. 139–151.
- Ogawa, R. dan Echizen, H., 2010. Drug-Drug Interaction Profiles of Proton Pump Inhibitors: *Clinical Pharmacokinetics*, **49**: 509–533.
- Ohnhaus, E.E., Berger, W., Duckert, F., dan Oesch, F., 1983. The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action: A drug interaction study. *Klinische Wochenschrift*, **61**: 851–858.
- Okumura, K., Komatsu, T., Yamashita, T., Okuyama, Y., Harada, M., Konta, Y., dkk., 2011. Time in the Therapeutic Range During Warfarin Therapy in Japanese Patients With Non-Valvular Atrial Fibrillation - A Multicenter Study of Its Status and Influential Factors -: – A Multicenter Study of Its Status and Influential Factors -. *Circulation Journal*, **75**: 2087–2094.
- O'Reilly, R.A., Trager, W.F., Rettie, A.E., dan Goulart, D.A., 1987. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. *Clinical Pharmacology and Therapeutics*, **42**: 290–294.
- Paciullo, F., Proietti, M., Bianconi, V., Nobili, A., Pirro, M., Mannucci, P.M., dkk., 2018. Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. *Drugs & Aging*, **35**: 365–373.
- Paludan-Müller, C., Vad, O.B., Stampe, N.K., Diederichsen, S.Z., Andreasen, L., Monfort, L.M., dkk., 2024. Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality. *European Heart Journal*, **45**: 2119–2129.

- Pandey, A., Gersh, B.J., McGuire, D.K., Shrader, P., Thomas, L., Kowey, P.R., dkk., 2016. Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation. *JACC: Clinical Electrophysiology*, **2**: 355–363.
- Parks, A.L., Frankel, D.S., Kim, D.H., Ko, D., Kramer, D.B., Lydston, M., dkk., 2024. Management of atrial fibrillation in older adults. *BMJ*, e076246.
- Patti, G., Pecen, L., Manu, M.C., Huber, K., Rohla, M., Renda, G., dkk., 2020. Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. *International Journal of Cardiology*, **318**: 67–73.
- Pokorney, S.D., Simon, D.N., Thomas, L., Fonarow, G.C., Kowey, P.R., Chang, P., dkk., 2015a. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. *American Heart Journal*, **170**: 141-148.e1.
- Pokorney, S.D., Simon, D.N., Thomas, L., Fonarow, G.C., Kowey, P.R., Chang, P., dkk., 2015b. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. *American Heart Journal*, **170**: 141-148.e1.
- Pothineni, N.V. dan Vallurupalli, S., 2018. Gender and Atrial Fibrillation: Differences and Disparities. *US Cardiology Review 2018;12(2):103–6.*, .
- Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Boriani, G., Castella, M., dkk., 2020. The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC).
- Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Boriani, G., Castella, M., dkk., n.d. The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC).
- Prana Jagannatha, G., Putra Swi Antara, I.M., Surya Pradnyana, I.W.A., dan Kamardi, S., 2023. Optimal international normalized ratio target in east asian populations with atrial fibrillation: systematic review and meta-analysis. *European Heart Journal*, **44**: ehac779.023.
- Rafaqat, S., Gluscevic, S., Patoulis, D., Sharif, S., dan Klisic, A., 2024. The Association between Coagulation and Atrial Fibrillation. *Biomedicines*, **12**: 274.
- Raina, R., Kaushik, M., Mahajan, S., Thakur, R., dan Banyal, V., n.d. Rare Interaction of Warfarin and Digoxin in a Case of Digoxin Toxicity.

- Reiffel, J.A., 2017. Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials: Useful, but Also Misleading, Misused, and Overinterpreted. *Circulation*, **135**: 1475–1477.
- Rivera-Caravaca, J.M., Roldán, V., Esteve-Pastor, M.A., Valdés, M., Vicente, V., Lip, G.Y.H., dkk., 2017. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. *Scientific Reports*, **7**: 12066.
- Ryczkowska, K., Adach, W., Janikowski, K., Banach, M., dan Bielecka-Dabrowa, A., 2023. Menopause and women’s cardiovascular health: is it really an obvious relationship? *Archives of Medical Science*, **19**: 458–466.
- Saliba, W., Gronich, N., Barnett-Griness, O., dan Rennert, G., 2016. The role of CHADS2 and CHA2DS2-VASc scores in the prediction of stroke in individuals without atrial fibrillation: a population-based study. *Journal of Thrombosis and Haemostasis*, **14**: 1155–1162.
- Scarpello, J.H.B., Hodgson, E., dan Howlett, H.C.S., 1998. Effect of metformin on bile salt circulation and intestinal motility in Type 2 diabetes mellitus. *Diabetic Medicine*, **15**: 651–656.
- Schmitt, L., Speckman, J., dan Ansell, J., 2003. Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range. *Journal of Thrombosis and Thrombolysis*, **15**: 213–216.
- Schnabel, R.B., Pecun, L., Ojeda, F.M., Lucerna, M., Rzayeva, N., Blankenberg, S., dkk., 2017. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. *Heart*, **103**: 1024–1030.
- Schnabel, R.B., Yin, X., Gona, P., Larson, M.G., Beiser, A.S., McManus, D.D., dkk., 2015. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *The Lancet*, **386**: 154–162.
- Senoo, K., Lau, Y.C., dan Lip, G.Y., 2014. Updated NICE guideline: management of atrial fibrillation (2014). *Expert Review of Cardiovascular Therapy*, **12**: 1037–1040.
- Shaik, A.N., Bohnert, T., Williams, D.A., Gan, L.L., dan LeDuc, B.W., 2016. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. *Journal of Pharmaceutical Sciences*, **105**: 1976–1986.
- Simone Joseph V., Abildgaard Charles F., dan Sghulman Irving, 1965. Blood Coagulation in Thyroid Dysfunction. *New England Journal of Medicine*, **273**: 1057–1061.

- Smith, S., Hogan, A.R., dan Richow, W., 2024. Impact of Time in Therapeutic Range on Adverse Events in Atrial Fibrillation Patients in an Ambulatory Care Setting. *Hospital Pharmacy*, 00185787241303914.
- Staszewski, J., Bilbin-Bukowska, A., Szymowski, W., Mejer-Zahorowski, M., dan Stępień, A., 2019. Cerebrovascular accidents differ between patients with atrial flutter and patients with atrial fibrillation. *Archives of Medical Science*.
- Tadesse, T.A., Tegegne, G.T., Yadeta, D., Chelkaba, L., dan Fenta, T.G., 2022. Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review. *Thrombosis Journal*, **20**: 58.
- Tantry, U.S., Kereiakes, D.J., dan Gurbel, P.A., 2011. Clopidogrel and Proton Pump Inhibitors. *JACC: Cardiovascular Interventions*, **4**: 365–380.
- Thomas, T.P. dan Grisanti, L.A., 2020. The Dynamic Interplay Between Cardiac Inflammation and Fibrosis. *Frontiers in Physiology*, **11**: 529075.
- Tomita, H., Kadokami, T., Momii, H., Kawamura, N., Yoshida, M., Inou, T., dkk., 2013. Patient Factors against Stable Control of Warfarin Therapy for Japanese Non-valvular Atrial Fibrillation Patients. *Thrombosis Research*, **132**: 537–542.
- Turk, U.O., Tuncer, E., Alioglu, E., Yuksel, K., Pekel, N., Ozpelit, E., dkk., 2015. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry. *Cardiology Journal*, **22**: 567–575.
- Vamos, M., Erath, J.W., dan Hohnloser, S.H., 2015. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. *European Heart Journal*, **36**: 1831–1838.
- Vesell Elliot S., Passananti G. Thomas, dan Greene Frank E., 1970. Impairment of Drug Metabolism in Man by Allopurinol and Nortriptyline. *New England Journal of Medicine*, **283**: 1484–1488.
- Wang, A., Green, J.B., Halperin, J.L., dan Piccini, J.P., 2019. Atrial Fibrillation and Diabetes Mellitus. *Journal of the American College of Cardiology*, **74**: 1107–1115.
- Wang, L., Ze, F., Li, J., Mi, L., Han, B., Niu, H., dkk., 2021. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. *Heart*, **107**: 881–887.
- Wang, T.J., Parise, H., Levy, D., D'Agostino, R.B., Wolf, P.A., Vasan, R.S., dkk., 2004. Obesity and the Risk of New-Onset Atrial Fibrillation.

- Watson, T., Shantsila, E., dan Lip, G.Y., 2009. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *The Lancet*, **373**: 155–166.
- Weil, B.R. dan Ozcan, C., 2015. Cardiomyocyte Remodeling in Atrial Fibrillation and Hibernating Myocardium: Shared Pathophysiologic Traits Identify Novel Treatment Strategies? *BioMed Research International*, **2015**: 1–8.
- Wiggins, B.S., Saseen, J.J., Page, R.L., Reed, B.N., Sneed, K., Kostis, J.B., dkk., 2016. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*, **134**: .
- Wight, T.N. dan Potter-Perigo, S., 2011. The extracellular matrix: an active or passive player in fibrosis? *American Journal of Physiology-Gastrointestinal and Liver Physiology*, **301**: G950–G955.
- Wijnen, J.C.F., Van De Riet, I.R., Lijfering, W.M., dan Van Der Meer, F.J.M., 2014. Metformin use decreases the anticoagulant effect of phenprocoumon. *Journal of Thrombosis and Haemostasis*, **12**: 887–890.
- Wong, C.X., Sullivan, T., Sun, M.T., Mahajan, R., Pathak, R.K., Middeldorp, M., dkk., 2015. Obesity and the Risk of Incident, Post-Operative, and Post-Ablation Atrial Fibrillation. *JACC: Clinical Electrophysiology*, **1**: 139–152.
- Xiu-Hua Zhang, X.-H.Z., Ren-Ai Xu, R.-A.X., Zhi-Sheng Xu, Z.-S.X., dkk., 2013. Effects of repeated allopurinol administration on rat cytochrome P450 activity 365–368.
- Yamasaki, K., Chuang, V.T.G., Maruyama, T., dan Otagiri, M., 2013. Albumin–drug interaction and its clinical implication. *Biochimica et Biophysica Acta (BBA) - General Subjects*, **1830**: 5435–5443.
- Yang, J., Song, C., Ding, H., Chen, M., Sun, J., dan Liu, X., 2022. Numerical study of the risk of thrombosis in the left atrial appendage of chicken wing shape in atrial fibrillation. *Frontiers in Cardiovascular Medicine*, **9**: 985674.
- Yoon, C.W. dan Bushnell, C.D., 2023. Stroke in Women: A Review Focused on Epidemiology, Risk Factors, and Outcomes. *Journal of Stroke*, **25**: 2–15.
- Yuniadi, Y., Hanafy, D.A., Rahardjo, S.B., Tondas, A.E., Maharani, E., Hermanto, D.Y., dkk., 2015. 2014 Indonesian Heart Association Guidelines of Management of Atrial Fibrillation. *Indonesian Journal of Cardiology*, 102–33.
- Zirlik, A. dan Bode, C., 2017. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. *Journal of Thrombosis and Thrombolysis*, **43**: 365–379.